FRANCE – Coave Therapeutics, a clinical-stage biotechnology company, has received funding worth US$39m from eureKARE , a pioneering new company focused on financing and building next generation biotechnology companies, during a series B round. The financing was led by Seroba Life Sciences, supported by new investors Théa Open Innovation and eureKARE alongside existing shareholders Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital, and Sham Innovation Santé/Turenne. Coave Therapeutics will use the proceeds from this fundraising to support the execution of its corporate strategy that involves the advancements of…
Read MoreCoave Therapeutics receives €33m (US$39m) worth of funding to help execute its corporate strategy
